Search Results
Results found for "OMass Therapeutics"
- Hop in the Time Machine with GPCR: Unraveling the Future of Research! ⦿ Nov 24 - Dec 1, 2024
How Structural Biology Informs the Development of Drugs Targeting G Protein-Coupled Receptors ARTICA THERAPEUTICS GPCR Jobs NEW GPCR Molecular Pharmacologist Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic
- 📰 GPCR Weekly News, February 27 to March 5, 2023
Industry News Design Pharmaceuticals has a new website Confo Therapeutics Announces Global Licensing Antiverse raises €2.8M for its computational antibody drug discovery platform Antiverse identifies therapeutic
- GPCRs are not simple on-off switches: deep dive into GPCR-ligand interactions
theoretically offer several advantages compared to orthosteric ligands when considered as potential therapeutic other GPCR-regulated systems such as free fatty acid receptors (FFARs), now regarded as targets for therapeutic
- Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage ...
Matt Barnes appointed President of Heptares Therapeutics Ltd., and Head of UK R&D Tokyo, Japan and Cambridge
- Pharmacophore-guided Virtual Screening to Identify New β 3 -adrenergic Receptor Agonists
It is a therapeutic target because it plays a role in thermogenesis, lipolysis, and bladder relaxation
- Gαs and Gαq/11 protein coupling bias of two AVPR2 mutants (R68W and V162A) that cause nephrogenic di
consequently activated signaling pathways, and also may shed light on the development of more effective new therapeutics
- In vitro assays for the functional characterization of (psychedelic) substances at the serotonin...
their appearance on the (illicit) drug market, e.g. as new psychoactive substances, their potential therapeutic
- AlphaFold’s Breakthrough in GPCR Research: Revolutionizing Discovery, Yet Awaiting Experimental Proof
crucial for understanding how drugs can selectively target different receptor conformations to achieve therapeutic
- Combined docking and machine learning identify key molecular determinants of ligand pharmacological
September 2022 "G protein‐coupled receptors (GPCRs) are valuable therapeutic targets for many diseases
- Actions of Parathyroid Hormone Ligand Analogues in Humanized PTH1R Knockin Mice
PTH-related protein (PTHrP) ligands and analogues for their pharmacologic activities and potential therapeutic
- Luciferase-based GloSensor™ cAMP assay: Temperature optimization and application to cell-based kinet
kinetic studies "G protein-coupled receptors (GPCRs) are an important receptor superfamily and common therapeutic
- Precise druggability of the PTH type 1 receptor
PTHR signaling that could be extended to GPCRs to expedite discoveries of small molecules as novel therapeutic
- Cell-Type-Specific Effects of the Ovarian Cancer G-Protein Coupled Receptor (OGR1) on Inflammation..
Our results suggest that strategies to selectively target OGR1 expression may represent a novel therapeutic
- Induced Human Regulatory T Cells Express the Glucagon-like Peptide-1 Receptor
2022 "The glucagon-like peptide-1 receptor (GLP-1R) plays a key role in metabolism and is an important therapeutic
- Molecular creativity in drug discovery
Whether you’re designing the next assay, scouting a new therapeutic angle, or exploring career pivots
- G protein-coupled receptors that influence lifespan of human and animal models
substantial participation in a wide variety of processes of human pathophysiology and are one of the main therapeutic
- Canonical chemokine receptors as scavenging “decoys”
The scavenging function of CKRs should be considered when evaluating the safety and therapeutic efficacy
- Increased Anxiety-like Behaviors in Adgra1-/- Male But Not Female Mice are Attributable to...
regulating the PI3K/AKT/GSK-3β and MEK/ERK pathways in amygdalae of male mice, implicating a potential, therapeutic
- Differences across sexes on head-twitch behavior and 5-HT2A receptor signaling in C57BL/6J mice
2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), is receiving renewed attention for their potential therapeutic
- GPR15 expressed in T lymphocytes from RA patients is involved in leukocyte chemotaxis to the...
Our results suggest that GPR15/GPR15L have a pathogenic role in RA and their antagonizing could be a therapeutic
- PH-Binding Motif in PAR4 Oncogene: From Molecular Mechanism to Drug Design
Pc(4-4) may become a promising candidate for future therapeutic cancer treatment."
- G protein-biased GPR3 signaling ameliorates amyloid pathology in a preclinical Alzheimer's disease..
discrete and separable effects and provide proof of concept for the development of safer GPCR-targeting therapeutics
- Crinetics Pharmaceuticals announced the formation of an independently operated new company...
stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics
- Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID-19...
Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID-19 and Other Antibody Therapeutics
- Allosteric Binding Demystified: Smarter GPCR Drug Discovery
Breakthroughs this week: Decoding ADGRE5 signaling; Eli Lilly’s obesity pill vs Novo’s Wegovy; Certa Therapeutics
- GASP1 enhances malignant phenotypes of breast cancer cells and decreases their response to...
and stabilizing IGF1R, and suggests that it may serve as a valuable prognostic factor and potential therapeutic
- High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and...
particularly aggressive and heterogeneous disease with few effective targeted therapies and precision therapeutic
- TLR4 biased small molecule modulators
Biased pharmacological modulators provide potential therapeutic benefits, including greater pharmacodynamic
- 📰 GPCR Weekly News, June 10 to 16, 2024
synaptic depression in dorsolateral striatum of adult male mice Methods & Updates in GPCR Research RNA therapeutics
- Pharmacologic Models
How the Mass Action Law underpins nearly every model Future of Receptor Theory: Linkage vs.




